Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors Twenty-one patients received ...
Spliced variants of BRAF(V600E) lack key exons that encompass RAS-binding domain. Scientists say additional changes to the sequence of BRAF(V600E) that arise in melanoma tumors on repeated exposure to ...
BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor PD-0325901 to be studied in combination Combination approach will target RAS mutations common in many ...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
(RTTNews) - Ascletis Pharma Inc. said that China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for the in-house developed oral PD-L1 small ...
STAMFORD, Conn. and BASEL, Switzerland and BEIJING and CAMBRIDGE, Mass. and SAN MATEO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- MapKure, LLC, SpringWorks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback